2- to- biotech has identified a novel human peptide hormone (called P3) that is expressed in activated immune cells that belong to human innate immune response.

The company has developed, a platform technology, with several specific mAbs against P3 in order to treat autoimmune diseases. In in-vitro studies the mAbs were used to activated human peripheral white blood cells and showed a significant decrease of TNF-alpha and INF-gamma levels as opposed to IL-10.

Subsequent in-vivo studies with the P3- mAb in different autoimmune disease mice models (MS, IBD and type 1 diabetes) showed a strong anti inflammatory effects of the mAbs.

With reference to type 1 diabetes the effects of the P3-mAb was tested in the NOD-mouse model (females mice).